Pfizer seeks to prevent HIV
Wall Street Journal (subscription required), January 30, 2008
A new Pfizer Inc. HIV drug will soon be reformulated in an effort to prevent the transmission of the virus. The New York drug maker is expected to announce that it will license its new medicine, Selzentry, to a nonprofit that investigates ways to turn HIV medicines for infected patients into vaginal substances to prevent transmission to women during sex. The partnership offers a low-risk way for Pfizer to find out if the medicine could become a frequently taken drug, while potentially offering an empowering concept to women in the developing world.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- IOM Identifies GME Problems, Calls for Finance Changes
- Handshaking Spreads Germs. Get Over It.
- Healthcare Costs Start With What We Eat
- Revenue Cycles Get a Boost from Simple JPEG Files
- Hospitals Likely to Outsource ICD-10 at Launch
- Anatomy of 3 Health System Rebranding Efforts